[Clinical observations on cefuzonam in pediatrics].
Cefuzonam (L-105, CZON) was given intravenously to 20 pediatric patients with the following acute bacterial infections: 13 of bronchopneumonia and 1 each of tonsillitis, purulent cervical lymphadenitis and acute tonsillitis, laryngitis, bronchitis, pyothorax, purulent meningitis complicated with septic arthritis, and urinary tract infection. Good clinical responses were obtained in all of the 20 patients and bacterial eradication of all 16 strains. No side effect was observed except 3 cases of slight elevation of transaminase, and 1 case each of soft stool and eosinophilia. From the above clinical results, it appears that CZON is a useful antibiotic for the treatment of pediatric patients with various kinds of bacterial infections.
D000208:Acute Disease; D001170:Arthritis, Infectious / Q000188:drug therapy; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004653:Empyema / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D007827:Laryngitis / Q000188:drug therapy; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; C049934:cefuzonam; D015296:Ceftizoxime